Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (<i>CTNNB1</i>) mutations.

J Clin Pathol · 2025 · PMC12772540 · PMID 39653501

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

β-catenin and LEF1 immunohistochemistry were both predictive of relapse-free survival (RFS) (p<0.05) and in addition, LEF1 also predicted overall survival (OS) (p<0.05) in patients with endometrial carcinoma, whereas β-catenin staining did not reach statistical significance ( figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (&lt;i&gt;CTNNB1&lt;/i&gt;) mutations.

The sentences

Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (<i>CTNNB1</i>) mutations.